Rev Esp Quimioter 2015:28(4):214-216

Could ceftaroline be an alternative therapy for linezolid resistant Staphylococcus epidermidis infections in Intensive Care Medicine?     

                        
FRANCISCO JAVIER CANDEL, ELVIRA BAOS, MERCEDES NIETO, JUAN JOSÉ PICAZO              

Introduction. Coagulase negative Staphylococcus continues generating interest in critically ill patients, due to their infections in extended admissions, in instrumented patients and due to their described multidrug resistance, which include glycopeptide heterorresistance and the increase in oxazolidinone resistance. Ceftaroline is a new cephalosporin with activity against resistant gram-positives, which, being betalactam, may provide adequate safety profile in the critical ill patient. The aim of this study was to determine the activity of ceftaroline and other antimicrobial agents against methicillin and linezolid-resistant Staphylococcus epidermidis.
Material and methods. We studied susceptibility of ceftaroline, tigecycline, daptomycin and vancomycin in a total of sixty-eight methicillin and linezolid-resistant S. epidermidis isolates with clinical significance from an Intensive Care Unit, using E-test.
Results. All strains were susceptible to the four antimicrobial agents, regardless of the level of resistance to linezolid.
Conclusion. Ceftaroline could be an alternative in the treatment of methicillin and linezolid-resistant S. epidermidis infections in critically ill patients.

Rev Esp Quimioter 2015:28(4):214-216 [pdf]

/por

Rev Esp Quimioter 2015:28(5):235-241

Boosted protease inhibitor monotherapy in HIV-infected patients: results of a study in a real life setting     

                        
NICOLÁS DI BENEDETTO, MARTA MONTERO-ALONSO, MARINO BLANES, JOSÉ LACRUZ, SANDRA CUELLAR, EVA CALABUIG, JOSÉ LÓPEZ, MIGUEL SALAVERT              

Background. Boosted protease inhibitor monotherapy may offer antiviral efficacy while reducing drug interactions, costs and toxicity. The aim of this study was to assess the efficacy of darunavir/ritonavir (DRV/r) and lopinavir/ritonavir (LPV/r) monotherapy in a real life setting.
Methods. A retrospective analysis of all HIV infected patients, who had initiated DRV/r or LPV/r monotherapy, was performed. Patients whose HIV viral load had remained undetectable for at least two consecutive follow-up visits and who had no neurocognitive disorder or hepatitis B co-infection, were included.
Results. Sixty patients were included. The median (IQR) time to follow-up was 66 (33-118) weeks. The proportions (CI95%) of patients with virological failure were 6.3% (1.7- 20.2) and 25.0% (12.7-43.4), respectively, in the DRV/r and LPV/r groups (p= 0.0424). The proportions (CI95%) of patients with therapeutic success were 90.6% (80.5-100) in the DRV/r group and 60.7% (42.6-78.8) in the LPV/r group (p=0.0063). No protease inhibitor mutations were detected. During the follow-up, 6 patients with dyslipidemia normalized their lipid values. The median monthly cost was 410 (IQR 242-416) euros per person lower for the monotherapy than for the combined antiretroviral therapy.
Conclusions. Boosted protease inhibitor monotherapy was effective in a real life setting. This study showed differences in favour of DRV/r as compared with LPV/r in terms of therapeutic success; however prospective studies are needed to confirm these results. Finally, although this study was not specifically designed to detect benefits in terms of costs and lipid profile, it shows evidence of a positive impact of monotherapy in these fields.

Rev Esp Quimioter 2015:28(5):235-241 [pdf]

/por

Rev Esp Quimioter 2016,29(1):40-43

Adherence to international recommendations in the fight against antimicrobial resistance – Substantial difference between outpatient consumption in Spain and Denmark     

                        

SARA MALO, MARÍA JOSÉ RABANAQUE, LARS BJERRUM              

Introduction. Increasing antibiotic resistance represents a major public health threat that jeopardises the future treatment of bacterial infections. This study aims to describe the adherence to recommendations proposed by the World Health Organization (WHO) Advisory Group on Integrated Surveillance of Antimicrobial Resistance (AGISAR), in Spain and Denmark, and to analyse the relation between the outpatient use of Critically Important Antimicrobials (CIA) and the bacterial resistance rates to these agents.
Material and methods. The Antimicrobial consumption interactive database (ESAC-Net) and Antimicrobial resistance interactive database (EARS-Net) provided data on outpatient use (2010-2013) of CIA (fluoroquinolones, macrolides, and 3rd and 4th generation cephalosporins) and the percentages of isolates of the main pathogens causing serious infections, resistant to these agents.
Results. The use of cephalosporins and fluoroquinolones, as well as the percentage of bacteria resistant, is higher in Spain than in Denmark. Although consumption of macrolides in both countries is similar, the proportion of Streptococcus pneumoniae resistant to macrolides is significantly higher in Spain.
Conclusion. The high outpatient consumption of CIA agents in Spain deviates substantially from the WHO recommendations. Moreover, it has the effect of elevated rates of antimicrobial resistance, that are lower in Denmark.

Rev Esp Quimioter 2016;29(1):40-43 [pdf]

/por

Rev Esp Quimioter 2016, 29(4):175-182

How should we approach Aspergillus in lung secretions of patients with COPD?   

                    

JOSÉ BARBERÁN, FRANCISCO JAVIER CANDEL, ANA ARRIBI             

Aspergillus spp. is frequently isolated in respiratory samples from patients with severe COPD; however, the clinical significance of this mold is unclear and its presence may indicate temporary passage, benign chronic carriage, or onset of invasive disease. The definitive diagnosis of pulmonary aspergillosis in COPD patients is often difficult owing to the lack of specific clinical and radiological signs. However, retrospective studies show the risk for developing pulmonary aspergillosis in older patients with severe COPD, and a high number of comorbidities who have received treatment with corticosteroids and/or broad spectrum antibioties. The development of algorithms based on microbiological and radiological data and risk factors for pulmonary aspergillosis can help to differentiate between colonization and infection.

Rev Esp Quimioter 2016; 29(4):175-182 [pdf]

/por

Rev Esp Quimioter 2016, 29(Suppl. 1):6-9

Epidemiology of the infection by resistant Gram-positive microorganisms                    

EMILIA CERCENADO          

Resistance among Gram-positive microorganisms to classical and new antimicrobials is a therapeutic threat. In Spain, methicillin resistance among Staphylococcus aureus (25-30%) and coagulase-negative staphylococci (50-60%) seems to have stabilized in the last decade. Among enterococci, vancomycin resistance is less than 5%. Both linezolid and daptomycin, in general, show good activity against these microorganisms. However, the resistance rates of Staphylococcus epidermidis to linezolid (20.9%), and of Enterococcus faecium to daptomycin (10.5%) in isolates from intensive care units are a worrying.

Rev Esp Quimioter 2016; 29(Suppl. 1):6-9 [pdf]

/por

Rev Esp Quimioter 2016, 29(6):328-331

Evaluation of a new device for sample collection, transport and detection of Group B Streptococcus in pregnant women                     

ALBERTO TENORIO-ABREU, JOSÉ ANTONIO GÓMEZ-FERNÁNDEZ, LUIS ARROYO-PEDRERO, ESMERALDA RODRÍGUEZ-MOLINS          

We have designed a new device that combines sample collection, transportation, culture and detection of Group B Streptococcus (GBS), requiring no additional processing in the clinical laboratory. The objective was to evaluate the performance of this device for GBS detection in pregnant women. The new prototype was compared to direct plating of vaginal-rectal swabs onto Granada solid media plates. Direct plating method detected 124 positive samples out of 600 (20.6%) whereas the new device detected 10 additional positive samples (134/600, 22.3%). This new device (patent-protected) could be considered for routine GBS screening.

Rev Esp Quimioter 2016; 29(6):328-331 [pdf]

/por

Rev Esp Quimioter 2017, 30(2):79-83

Favipiravir, a new concept of antiviral drug against influenza viruses                     

JORDI REINA, NURIA REINA           

Favipiravir (T-705) is a new antiviral drug with strong inhibitory activity on RNA-dependent RNA polymerase of most RNA virus genome. All the influenza viruses have been shown fully sensitive to this new antiviral, including genetic strains to neuraminidase inhibitors (oseltamivir) resistance. Its mechanism of action lies in blocking viral replication and induction of lethal mutagenesis which determines the loss of infective activity of influenza viruses. Its activity is particularly intense in the respiratory tract, decreasing the viral load to non-infectious levels. Clinical trials in humans have not yet completed but have very favourable results. It seems that the best therapy would be the combination of favipiravir with oseltamivir; both antivirals are synergistic and avoid the emergence of resistance.

Rev Esp Quimioter 2017; 30(2):79-83  [pdf]

/por

Rev Esp Quimioter 2015:28(2):98-100

Phenotypic methods for detection of methicillin-resistant Staphylococcus aureus                                 
 


GERTRUDIS HORNA, LIZETH ASTOCONDOR, JAN JACOBS, CORALITH GARCÍA              

 
Background.  Cefoxitin is a potent inducer of the mecA gene. It is currently as a screening recommended method for presumptive identification of isolates of methicillin resistant Staphylococcus aureus (MRSA). The aim of the study was to compare the sensitivity and specificity of the cefoxitin disc diffusion (30μg) to oxacillin agar screening from detection of the mecA gene by PCR.
Methods. Three hundred thirty-one strains of S. aureus isolated from blood cultures of patients from hospitals in Lima were used in the study. The following tests were performed: oxacillin screening agar (plates were inoculated with 4% NaCl and 6 mg/L of oxacillin), cefoxitin disc diffusion test (30 ug) and PCR to amplify the mecA gene.
Results.  The mecA gene was detected in 165 out of 331 S. aureus isolates. Thus, the frequency of detection of MRSA was 50%. The evaluation of the cefoxitin disc diffusion test showed a 96.3% and 90.9% of sensitivity and specificity, respectively.
Conclusion. Cefoxitin disc diffusion test correlated well with detection of the mecA gene by PCR. Therefore, this test can be an alternative to PCR for detection of MRSA in limited resources settings.

Rev Esp Quimioter 2015:28(2):98-100 [pdf]

/por

Rev Esp Quimioter 2015:28(Suppl. 1):1-4

Update in Infectious Diseases 2015     

                        
FRANCISCO JAVIER CANDEL, LAURA LÓPEZ GONZÁLEZ, ANA BELÉN GARCÍA-GARCÍA, FLAVIA CHIARELLA, JUAN JOSÉ PICAZO              

Infectious disease remains current worldwide. During the second half of 2014 an outbreak of ebolavirus hit West Africa with implications in the rest of the world. In fact, Spain declared the first imported case of this infection. Multiresistant enterobacteria outbreaks are emerging all around the world in a moment on which WHO draws attention to the limited resources, coining the term “post antibiotic era”. On the other hand, 2014 went down in history as one in which hepatitis C is cured. Are also current HIV epidemiological control or strategies for antiviral and antifungal prophylaxis in immunocompromised hosts.

Rev Esp Quimioter 2015:28(Suppl. 1):1-4 [pdf]

/por

Rev Esp Quimioter 2015:28(5):242-246

Vitek MS matrix-assisted laser desorption ionization-time of flight mass spectrometry for identifying respiratory bacterial pathogens: a fast and efficient method     

                        
Mª FÁTIMA LÓPEZ-FABAL, JOSÉ LUÍS GÓMEZ-GARCÉS, JOSÉ LUÍS LÓPEZ-HONTANGAS, NURIA SANZ, CARMEN MUÑOZ, MARTA REGODÓN              

Mass spectrometry has become a reference resource for identifying microorganisms in clinical microbiology services. One hundred and fifty one clinical isolates were selected from respiratory specimens routinely identified as Streptococcus pneumoniae (43), Haemophilus influenzae (64) and Moraxella catarrhalis (44). These identifications were compared with other phenotypical methods and mass spectrometry (MALDI-TOF-MS Vitek). Result discrepancies were assessed by 16S rRNA sequencing. Thirty-eight of the 43 strains of S. pneumoniae (86%) were identified as such using phenotypical methods and spectrometry. In 5 cases, MALDI-TOF identified 4 of them as Streptococcus pseudopneumoniae and 1 as S. mitis/oralis. Forty-eight of the 64 strains were identified as H. influenzae (75%) using biochemical identification systems and automated identification systems, whereas MALDI-TOF-MS Vitek identified 51 strains (79%) as such. Conventional methods and spectrometry identified all the 40 strains tested (100%) as M. catarrhalis. All strains with discrepant results were sequenced, and in all cases, the identification obtained by spectrometry was confirmed. The results obtained in this study show that mass spectrometry provides identification of these bacteria faster and in a more reliable way than those based on conventional phenotypical methods.

Rev Esp Quimioter 2015:28(5):242-246 [pdf]

/por